Results 81 to 90 of about 2,461,363 (302)

Impact of antiplatelet therapy in heart disease

, 2012
Because platelet activation plays an important pathophysiological role in acute coronary syndromes, antiplatelet agents are a mainstay of cardiovascular therapy, both in high-risk primary prevention and in secondary prevention.
DE CATERINA, Raffaele, RENDA, GIULIA
core   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Dual antiplatelet therapy -- management in general practice.

, 2013
Background Prasugrel and ticagrelor are two new antiplatelet agents being used in the management of acute coronary syndromes. The number of patients in the community managed on these medications is growing, and thus, it is essential that general ...
Adsett, Geoffrey, Markham, Ryan, Jayasinghe, Rohan   +2 more
core  

Individualized antiplatelet therapy

, 2009
SummarySafeguarding of antiplatelet drug efficacy represents a cornerstone for the optimal treatment of patients with symptomatic coronary artery disease requiring coronary interventions.
T. Geisler, M. Gawaz
core   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Antiplatelet therapy in elderly [PDF]

, 2008
The aim of our study was to determine the efficacy of antiplatelet therapy in elderly and polymorbid patients. We were interested to know whether selected laboratory parameters, co-existing conditions, and concomitant therapy may affect the antiplatelet ...
Paluch, Zoltán
core  

Impact of Antiplatelet Therapy During Endovascular Therapy for Tandem Occlusions

, 2020
International audienceBackground and Purpose- Antiplatelet agents could be used in the setting of endovascular therapy for tandem occlusions to reduce the risk of de novo intracranial embolic migration, reocclusion of the extracranial internal carotid ...
Darcourt, Julien, Guenego, Adrien, Blanc, Raphaël, Anadani, Mohammad, Mazighi, Mikael, Spiotta, Alejandro, Derelle, Anne-Laure, Nogueira, Raul, Psychogios, Marios, Hecker, Corentin, Richard, Sébastien, Liao, Liang, Ribo, Marc, Renieri, Leonardo, Lapergue, Bertrand, Houdart, Emmanuel, Redjem, Hocine, Boutchakova, Maria, Muchada, Maria Muchada, Labreuche, Julien, Consoli, Arturo, Killer-Oberpfalzer, Monika, Kastrup, Andreas, Mione, Gioia, Christopher, Maurer, Zhu, François, Grossberg, Jonathan Andrew, Nogueira, Raul G., Eiden, Sebastian, Lockau, Johanna, Vukasinovic, Isabelle, Holtmannspötter, Markus, Riou-Comte, Nolwenn, Haussen, Diogo C., Piotin, Michel, Cognard, Christophe, Siddiqui, Adnan H., Taschner, Christian, Rodesch, Georges, Davies, Jason, Labeyrie, Marc-Antoine, Shallwani, Hussain, Psychogios, Marios N., Papanagiotou, Panagiotis, Steglich-Arnholm, Henrik, Mangiafico, Salvatore, Tonnelet, Romain, Anxionnat, René, Behme, Daniel, Lacour, Jean-Christophe, Siddiqui, Adnan, Turjman, Francis, Bracard, Serge, Pomero, Elisa, Dorn, Franziska, Biondi, Alessandra, Haussen, Diogo, Humbertjean, Lisa, Gory, Benjamin   +58 more
core   +1 more source

Preclinical Serial Assessment of Virtual Physiology After Implantation of a Novel Endoluminal Resorbable Fibrillated Scaffold

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background The resorbable fibrillated scaffold (RFS) is a novel electrospun, polylactide‐based endoluminal scaffold developed for peripheral arterial applications. Its porous microfibre architecture is intended to support host cell infiltration and vascular restoration.
Kotaro Miyashita, Lucas Hatzikostas, Emiliano Bianchini, Milosz Dziarmaga, Chun‐Ting Shih, Jouke Dijkstra, Eric K. W. Poon, Bart Sanders, Golo von Basum, Rick de Vries, Kim van Noort, Marc van Sambeek, Jos C. van den Berg, Albert Chinhenzva, Scot Garg, Yoshinobu Onuma, Patrick W. Serruys   +16 more
wiley   +1 more source

Rationale and Design of the CREATE Trial: A Multicenter, Randomized Comparison of Continuation or Cessation of Single Antithrombotic Therapy at 1 Year After Transcatheter Aortic Valve Replacement

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Current guidelines and expert consensus recommend lifelong single antiplatelet therapy for patients undergoing transcatheter aortic valve replacement who have no indication for anticoagulation or dual antiplatelet therapy. However, there is no
Ran Liu, Yang Li, Lihua Zhang, Zhinan Lu, Zhaolin Fu, Thomas Modine, Hasan Jilahawi, Stuart Pocock, Yongjian Wu, Guangyuan Song   +9 more
doaj   +1 more source

The preventive effect of antiplatelet therapy in acute respiratory distress syndrome: a meta-analysis

Critical Care, 2018
Background Acute respiratory distress syndrome (ARDS) is a life-threatening condition with high mortality that imposes a serious medical burden. Antiplatelet therapy is a potential strategy for preventing ARDS in patients with a high risk of developing ...
Yingqin Wang, Ming Zhong, Zhichao Wang, Jieqiong Song, Wei Wu, Duming Zhu   +5 more
doaj   +1 more source